Anti-Human LAG-3 Recombinant Nanobody (SAA2195) (HB613013)

Name: Anti-Human LAG-3 Recombinant Nanobody (SAA2195)
Brand: abinScience
SKU: HB613013
Price: 126 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

20ug
50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HB613013

Description

Anti-Human LAG3 Nanobody (SAA2195) [SAA2195] (HB613013) is a alpaca monoclonal antibody detecting LAG3 in ELISA. Suitable for Human.

Reactivité des espèces

Human

Applications

ELISA

Espèce hôte

Alpaca

Clonalité

Monoclonal

Isotype

VHH-8His-Cys-tag

ID de clone

SAA2195

Cible

CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3

Niveau d'endotoxines

< 10 EU/mg

Pureté

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Numéro d'accès

P18627

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648

2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082

3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750

4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185

5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966

6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841

7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469

8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152

10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human LAG3 Nanobody (SAA2195)

Reférences

Fiche technique

Anti-Human LAG-3 Recombinant Nanobody (SAA2195).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Protéines Recombinantes

Anticorps

Kits d'Essai